Albumin fusion proteins
First Claim
1. An albumin fusion protein comprising an interferon alpha polypeptide fused to an albumin polypeptide wherein said albumin fusion protein is produced from an isolated host cell comprising Construct ID 3165.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
Citations
83 Claims
-
1. An albumin fusion protein comprising an interferon alpha polypeptide fused to an albumin polypeptide wherein said albumin fusion protein is produced from an isolated host cell comprising Construct ID 3165.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 66, 67, 68, 69, 70, 71)
-
2. The albumin fusion protein of claim 1, which is glycosylated.
-
3. The albumin fusion protein of claim 1, which is non-glycosylated.
-
4. The albumin fusion protein of claim 1, wherein said isolated host cell is yeast.
-
5. The albumin fusion protein of claim 4, wherein said yeast is a Saccharomyces cerevisiae.
-
6. The albumin fusion protein of claim 4, wherein said yeast is glycosylation deficient.
-
7. The albumin fusion protein of claim 4, wherein said yeast is glycosylation and protease deficient.
-
8. The albumin fusion protein of claim 1, wherein said isolated host cell is a mammalian cell.
-
9. The albumin fusion protein of claim 8, wherein said mammalian cell is a COS cell, a CHO cell, or a NSO cell.
-
10. The albumin fusion protein of claim 1, wherein the albumin fusion protein further comprises a secretion leader sequence.
-
11. A composition comprising the albumin fusion protein of claim 1 and a pharmaceutically acceptable carrier.
-
33. A nucleic acid molecule comprising a polynucleotide encoding the albumin fusion protein of claim 1.
-
34. The nucleic acid molecule of claim 33, which encodes the albumin fusion protein further comprising an N-terminal methionine.
-
35. The nucleic acid molecule of claim 33, which encodes the albumin fusion protein further comprising a signal sequence.
-
36. The nucleic acid molecule of claim 33, which comprises a heterologous polynucleotide.
-
37. The nucleic acid molecule of claim 36, wherein said heterologous polynucleotide is at least one selected from a vector sequence, a promoter sequence, a selectable marker, and a region for termination of transcription.
-
38. The nucleic acid molecule of claim 33, which is part of an expression cassette.
-
39. A vector comprising the nucleic acid molecule of claim 33.
-
40. An isolated host cell comprising the nucleic acid molecule of claim 33.
-
41. An isolated host cell comprising the vector of claim 39.
-
42. A method of producing an albumin fusion protein comprising:
-
(a) culturing the isolated host cell of claim 40 in conditions such that the albumin fusion protein is expressed; and (b) recovering the albumin fusion protein.
-
-
43. The albumin fusion protein produced by the method of claim 42.
-
66. The isolated host cell of claim 40, which is prokaryotic.
-
67. The isolated host cell of claim 40, which is eukaryotic.
-
68. The isolated host cell of claim 67, which is a yeast cell.
-
69. The isolated host cell of claim 68, wherein said yeast cell is Saccharomyces cerevisiae.
-
70. The isolated host cell of claim 67, which is a mammalian cell.
-
71. The isolated host cell of claim 70, wherein said mammalian cell is a COS cell, a CHO cell, or a NSO cell.
-
2. The albumin fusion protein of claim 1, which is glycosylated.
-
12. An albumin fusion protein comprising an interferon alpha polypeptide fused to an albumin polypeptide, wherein said albumin fusion protein is produced from an isolated host cell comprising the construct contained in ATCC Deposit No. PTA-4670.
- View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 72, 73, 74, 75, 76, 77)
-
13. The albumin fusion protein of claim 12, which is glycosylated.
-
14. The albumin fusion protein of claim 12, which is non-glycosylated.
-
15. The albumin fusion protein of claim 12, wherein said isolated host cell is yeast.
-
16. The albumin fusion protein of claim 15, wherein said yeast is Saccharomyces cerevisiae.
-
17. The albumin fusion protein of claim 15, wherein said yeast is glycosylation deficient.
-
18. The albumin fusion protein of claim 15, wherein said yeast is glycosylation and protease deficient.
-
19. The albumin fusion protein of claim 12, wherein said isolated host cell is a mammalian cell.
-
20. The albumin fusion protein of claim 19, wherein said mammalian cell is a COS cell, a CHO cell, or a NSO cell.
-
21. A composition comprising the albumin fusion protein of claim 12 and a pharmaceutically acceptable carrier.
-
44. A nucleic acid molecule comprising a polynucleotide encoding the albumin fusion protein of claim 12.
-
45. The nucleic acid molecule of claim 44, which encodes the albumin fusion protein further comprising an N-terminal methionine.
-
46. The nucleic acid molecule of claim 44, which encodes the albumin fusion protein further comprising a signal sequence.
-
47. The nucleic acid molecule of claim 44, which comprises a heterologous polynucleotide.
-
48. The nucleic acid molecule of claim 47, wherein said heterologous polynucleotide is at least one selected from a vector sequence, a promoter sequence, a selectable marker, and a region for termination of transcription.
-
49. The nucleic acid molecule of claim 44, which is part of an expression cassette.
-
50. A vector comprising the nucleic acid molecule of claim 44.
-
51. An isolated host cell comprising the nucleic acid molecule of claim 44.
-
52. An isolated host cell comprising the vector of claim 50.
-
53. A method of producing an albumin fusion protein comprising:
-
(a) culturing the isolated host cell of claim 51 in conditions such that the albumin fusion protein is expressed; and (b) recovering the albumin fusion protein.
-
-
54. The albumin fusion protein produced by the method of claim 53.
-
72. The isolated host cell of claim 51, which is prokaryotic.
-
73. The isolated host cell of claim 51, which is eukaryotic.
-
74. The isolated host cell of claim 73, which is a yeast cell.
-
75. The isolated host cell of claim 74, wherein said yeast cell is Saccharomyces cerevisiae.
-
76. The isolated host cell of claim 73, which is a mammalian cell.
-
77. The isolated host cell of claim 76, wherein said mammalian cell is a COS cell, a CHO cell, or a NSO cell.
-
13. The albumin fusion protein of claim 12, which is glycosylated.
-
22. An albumin fusion protein produced from an isolated host cell comprising a construct encoding an interferon alpha polypeptide fused to an albumin polypeptide, wherein said albumin fusion protein comprises amino acids 25 to 774 of SEQ ID NO:
- 1300.
- View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 78, 79, 80, 81, 82, 83)
-
23. The albumin fusion protein of claim 22, wherein said albumin fusion protein further comprises a secretion leader sequence.
-
24. The albumin fusion protein of claim 22, which is glycosylated.
-
25. The albumin fusion protein of claim 22, which is non-glycosylated.
-
26. The albumin fusion protein of claim 22, wherein said isolated host cell is yeast.
-
27. The albumin fusion protein of claim 26, wherein said yeast is Saccharomyces cerevisiae.
-
28. The albumin fusion protein of claim 26, wherein said yeast is glycosylation deficient.
-
29. The albumin fusion protein of claim 26, wherein said yeast is glycosylation and protease deficient.
-
30. The albumin fusion protein of claim 22, wherein said isolated host cell is a mammalian cell.
-
31. The albumin fusion protein of claim 30, wherein said mammalian cell is a COS cell, a CHO cell, or a NSO cell.
-
32. A composition comprising the albumin fusion protein of claim 22 and a pharmaceutically acceptable carrier.
-
55. A nucleic acid molecule comprising a polynucleotide encoding the albumin fusion protein of claim 22.
-
56. The nucleic acid molecule of claim 55, which encodes the albumin fusion protein further comprising an N-terminal methionine.
-
57. The nucleic acid molecule of claim 55, which encodes the albumin fusion protein further comprising a signal sequence.
-
58. The nucleic acid molecule of claim 55, which comprises a heterologous polynucleotide.
-
59. The nucleic acid molecule of claim 58, wherein said heterologous polynucleotide is at least one selected from a vector sequence, a promoter sequence, a selectable marker, and a region for termination of transcription.
-
60. The nucleic acid molecule of claim 55, which is part of an expression cassette.
-
61. A vector comprising the nucleic acid molecule of claim 55.
-
62. An isolated host cell comprising the nucleic acid molecule of claim 55.
-
63. An isolated host cell comprising the vector of claim 61.
-
64. A method of producing an albumin fusion protein comprising:
-
(a) culturing the isolated host cell of claim 62 in conditions such that the albumin fusion protein is expressed; and (b) recovering the albumin fusion protein.
-
-
65. The albumin fusion protein produced by the method of claim 64.
-
78. The isolated host cell of claim 62, which is prokaryotic.
-
79. The isolated host cell of claim 62, which is eukaryotic.
-
80. The isolated host cell of claim 79, which is a yeast cell.
-
81. The isolated host cell of claim 80, wherein said yeast cell is Saccharomyces cerevisiae.
-
82. The isolated host cell of claim 79, which is a mammalian cell.
-
83. The isolated host cell of claim 82, wherein said mammalian cell is a COS cell, a CHO cell, or a NSO cell.
-
23. The albumin fusion protein of claim 22, wherein said albumin fusion protein further comprises a secretion leader sequence.
Specification
- Resources
-
Current AssigneeNovozymes Biopharma DK A/S (Novozymes)
-
Original AssigneeHuman Genome Sciences Incorporated (GSK plc), Delta Biotechnology Limited (Sartorius AG)
-
InventorsTurner, Andrew J., Rosen, Craig A., Haseltine, William A., Ruben, Steven M., Ballance, David J.
-
Primary Examiner(s)Landsman; Robert
-
Assistant Examiner(s)Hissong; Bruce D.
-
Application NumberUS11/429,276Publication NumberTime in Patent Office1,233 DaysField of SearchNoneUS Class Current424/185.1CPC Class CodesA61K 31/155 Amidines (), e.g. guanidine...A61K 31/426 1,3-ThiazolesA61K 31/4439 containing a five-membered ...A61K 31/4965 Non-condensed pyrazinesA61K 38/00 Medicinal preparations cont...A61K 38/04 Peptides having up to 20 am...A61K 38/17 from animals; from humans e...A61K 38/28 InsulinsA61K 39/21 Retroviridae, e.g. equine i...A61P 1/02 Stomatological preparations...A61P 1/04 for ulcers, gastritis or re...A61P 1/16 for liver or gallbladder di...A61P 1/18 for pancreatic disorders, e...A61P 11/00 Drugs for disorders of the ...A61P 11/02 Nasal agents, e.g. deconges...A61P 11/06 AntiasthmaticsA61P 13/02 of urine or of the urinary ...A61P 13/08 of the prostateA61P 13/10 of the bladderA61P 13/12 of the kidneysA61P 15/00 : Drugs for genital or sexual...A61P 15/08 : for gonadal disorders or fo...A61P 15/10 : for impotenceA61P 17/00 : Drugs for dermatological di...A61P 17/02 : for treating wounds, ulcers...A61P 19/02 : for joint disorders, e.g. a...A61P 19/04 : for non-specific disorders ...A61P 19/06 : Antigout agents, e.g. antih...A61P 19/08 : for bone diseases, e.g. rac...A61P 21/00 : Drugs for disorders of the ...A61P 21/04 : for myasthenia gravisA61P 25/00 : Drugs for disorders of the ...A61P 25/10 : for petit-malA61P 25/16 : Anti-Parkinson drugsA61P 25/28 : for treating neurodegenerat...A61P 27/02 : Ophthalmic agentsA61P 27/06 : Antiglaucoma agents or mioticsA61P 27/16 : OtologicalsA61P 29/00 : Non-central analgesic, anti...A61P 3/00 : Drugs for disorders of the ...A61P 3/04 : Anorexiants; Antiobesity ag...A61P 3/06 : AntihyperlipidemicsA61P 3/08 : for glucose homeostasis pan...A61P 3/10 : for hyperglycaemia, e.g. an...A61P 3/12 : for electrolyte homeostasisA61P 3/14 : for calcium homeostasis vit...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/10 : AntimycoticsA61P 31/12 : AntiviralsA61P 31/14 : for RNA virusesA61P 31/16 : for influenza or rhinovirusesA61P 31/18 : for HIVA61P 31/20 : for DNA virusesA61P 31/22 : for herpes virusesA61P 33/00 : Antiparasitic agentsA61P 33/02 : Antiprotozoals, e.g. for le...A61P 33/06 : AntimalarialsA61P 35/00 : Antineoplastic agentsA61P 35/02 : specific for leukemiaA61P 35/04 : specific for metastasisA61P 37/02 : ImmunomodulatorsA61P 37/04 : ImmunostimulantsA61P 37/06 : Immunosuppressants, e.g. dr...A61P 37/08 : Antiallergic agents antiast...A61P 43/00 : Drugs for specific purposes...A61P 5/00 : Drugs for disorders of the ...A61P 5/06 : of the anterior pituitary h...A61P 5/14 : of the thyroid hormones, e....A61P 5/40 : Mineralocorticosteroids, e....A61P 5/50 : for increasing or potentiat...A61P 7/00 : Drugs for disorders of the ...A61P 7/04 : Antihaemorrhagics; Procoagu...A61P 7/06 : AntianaemicsA61P 7/12 : Antidiuretics, e.g. drugs f...A61P 9/00 : Drugs for disorders of the ...A61P 9/02 : Non-specific cardiovascular...A61P 9/04 : Inotropic agents, i.e. stim...A61P 9/06 : AntiarrhythmicsA61P 9/08 : Vasodilators for multiple i...A61P 9/10 : for treating ischaemic or a...A61P 9/12 : AntihypertensivesA61P 9/14 : Vasoprotectives; Antihaemor...C07K 14/005 : from virusesC07K 14/435 : from animals; from humansC07K 14/4713 : Autoimmune diseases, e.g. I...C07K 14/4723 : Cationic antimicrobial pept...C07K 14/475 : Growth factors; Growth regu...C07K 14/50 : Fibroblast growth factor [FGF]C07K 14/505 : Erythropoietin [EPO]C07K 14/51 : Bone morphogenetic factor; ...C07K 14/521 : ChemokinesC07K 14/525 : Tumour necrosis factor [TNF]C07K 14/535 : Granulocyte CSF; Granulocyt...C07K 14/54 : Interleukins [IL]C07K 14/5406 : IL-4C07K 14/55 : IL-2C07K 14/555 : Interferons [IFN]C07K 14/56 : IFN-alphaC07K 14/565 : IFN-betaC07K 14/575 : Hormones derived from pro-o...C07K 14/57563 : Vasoactive intestinal pepti...C07K 14/5759 : Products of obesity genes, ...C07K 14/585 : CalcitoninsC07K 14/59 : Follicle-stimulating hormon...C07K 14/60 : Growth hormone-releasing fa...C07K 14/605 : GlucagonsC07K 14/61 : Growth hormone [GH], i.e. s...C07K 14/62 : InsulinsC07K 14/635 : Parathyroid hormone, i.e. p...C07K 14/65 : Insulin-like growth factors...C07K 14/655 : SomatostatinsC07K 14/665 : derived from pro-opiomelano...C07K 14/705 : Receptors; Cell surface ant...C07K 14/7151 : for tumor necrosis factor [...C07K 14/765 : Serum albumin, e.g. HSAC07K 14/82 : Translation products from o...C07K 16/00 : Immunoglobulins [IGs], e.g....C07K 16/241 : Tumor Necrosis FactorsC07K 16/26 : against hormones ; against ...C07K 2317/10 : characterized by their sour...C07K 2317/622 : Single chain antibody (scFv)C07K 2317/76 : Antagonist effect on antige...C07K 2319/00 : Fusion polypeptideC07K 2319/20 : containing a tag with affin...C07K 2319/30 : Non-immunoglobulin-derived ...C07K 2319/31 : fusions, other than Fc, for...C07K 7/06 : having 5 to 11 amino acidsC12N 15/62 : DNA sequences coding for fu...C12N 2501/335 : Glucagon; Glucagon-like pep...C12N 2740/16111 : concerning HIV envC12N 2740/16122 : New viral proteins or indiv...C12N 2740/16134 : Use of virus or viral compo...C12N 2740/16171 : Demonstrated in vivo effectC12N 7/00 : Viruses; Bacteriophages; Co...C12N 9/0006 : acting on CH-OH groups as d...C12N 9/0008 : acting on the aldehyde or o...C12Y 101/01105 : Retinol dehydrogenase (1.1....C12Y 102/01 : with NAD+ or NADP+ as accep...C12Y 207/01095 : Kanamycin kinase (2.7.1.95)...